Skip to main content

Table 2 Percentage of early- and late-apoptotic/necrotic IGROV1 cells after treatment with MK1775 and 177Lu-DOTA-chCE7

From: Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma

IGROV1 Untreated control MK1775 [300 nM] 177Lu-DOTA-chCE7 [5.0 MBq/ml] Combined treatment
Early-apoptosis 4% ± 1 8% ± 2 29% ± 10 40% ± 4
Late-apoptosis/necrosis 9% ± 2 10% ± 2 13% ± 2 12% ± 1
  1. The data were generated from three independent flow cytometry experiments